Ceritinib has been granted Priority Review as a first-line treatment for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer.
E-cigarettes and replacement nicotine therapy deposit fewer harmful chemicals in the body that smoking.
Elderly with NSCLC have lower incidence of esophagitis, can tolerate aggressive radiation therapy.
Annual lung cancer screening of only high-risk smokers more cost-effective than current methods.
Researchers estimate that out of the 6.8 million current and former smokers eligible for lung cancer screening in 2015, only a fraction received it.
There are a growing number of NSCLC patients with advanced disease who are opting to forgo treatment despite the fact that receiving standard of care treatment leads to a higher OS.
A higher consumption of nuts was associated with a lower overall risk for developing lung cancer irrespective of smoking status.
Second study shows increase in lung cancer screening from 1.3 to 2.1 percent from 2010 to 2015
The addition of bevacizumab to first-line treatment with cisplatin plus etoposide improved PFS, but not OS, with an acceptable toxicity profile in patients with extensive-disease SCLC.
Treatment options for brain metastases in patients with EGFR-mutant NSCLC include SRS, WBRT, and EGFR TKIs. In this study, researchers sought to determine the optimal treatment approach of those who develop brain metastases and have not received EFGR TKIs.
Ceritinib is a kinase inhibitor indicated for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib; in this study, researchers determined the efficacy of ceritinib in patients with untreated ALK-rearranged NSCLC.
Study found 21 percent of those with late-stage non-small cell lung cancer went without therapy, even though it could boost survival.
Annual counseling could reduce prevalence and prevent many smoking-attributable fatalities.
Analyses of lung tumor specimens were used to determine whether mutational profiles of lung cancers differ between black and white patients. Such differences could explain differences in prognosis and lead to reductions in outcomes disparities.
Lung Cancer Navigator, a mobile, customizable app from LUNGEVITY, helps patients with lung cancer better understand their disease, manage medications, track symptoms, and access support.
Investigators report on trends in treatment of advanced-stage NSCLC from 2000 to 2011, including impact on survival and total Medicare spending.
Study evaluated differences in survival with respect to the time interval between tumor resection and initiation of postoperative chemotherapy in patients with NSCLC.
[Cancer Informatics] This research examinbed independent and joint performance of retrieving smoking status through different sources and compared the performance of retrieving smoking strength information from narrative text and PPI.
For patients with head and neck or lung cancer, stepped care programs may offer a more affordable yet effective approach.
The evolution of the diminishing role of extrapleural pneumonectomy in the surgical management of malignant pleural mesotheliomaDecember 22, 2016
[OncoTargets and Therapy] The surgical approach that offers the best outcomes for malignant pleural mesothelioma management is still debated. This research examines the efficacy of surgical treatment.
Carboplatin-paclitaxel with concurrent RT has comparable efficacy with cisplatin-etoposide plus RT in patients with stage III NSCLC.
The efficacy and safety of atezolizumab in patients with previously treated NSCLC was evaluated in the OAK trial, an open-label, pivotal, phase 3 study, the results of which were recently published.
Results of the METLung trial are presented. In this trial, researchers evaluated the efficacy and safety of onartuzumab in patients with advanced NSCLC selected by MET immunohistochemistry.
A study presented at the World Conference on Lung Cancer compared progression-free survival after treatment with osimertinib with that of platinum therapy plus pemetrexed in a select group of patients with T790M-positive advanced NSCLC.
Even patients that quit smoking in their 60s can add years to their lives, researchers find.
Among patients with non-small cell lung cancer (NSCLC), those with a mental health disorder appeared to have a higher risk of death.
IH-induced exosomes from mice significantly promote TC1 malignant properties, according to a recent study.
Fewer people smoking, but cancer burden still high in the U.S.
In a multicenter, open-label, phase 2 study, researchers evaluated the activity and safety of vandetanib in patients with advanced RET-rearranged NSCLC.
Researchers report on their evaluation of the efficacy and safety of vandetanib, a kinase inhibitor of VEGFR, EGFR, and the RET-tyrosine kinase, in patients with NSCLC tumors with chromosomal rearrangements involving RET.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|